SGLT2 inhibitors

197 - The science of obesity & how to improve nutritional epidemiology | David Allison, Ph.D

Peter Attia MD

A class of drugs mentioned as having life-prolonging effects for conditions associated with obesity.

#140 - Gerald Shulman, MD, PhD: Insulin resistance—molecular mechanisms and clinical implications

Peter Attia MD

A class of drugs that cause glucose loss in the urine, leading to calorie loss and some weight reduction, as well as mild reductions in liver fat.

#41–Jake Kushner, M.D.: How to thrive with T1D and the valuable insights that can benefit anyone

Peter Attia MD

A class of drugs that lower glucose by causing its excretion in urine, noted for leading to euglycemic DKA in some Type 1 and Type 2 Diabetes patients, but also for profound cardiovascular benefits.

#134 - James O’Keefe, M.D.: Preventing cardiovascular disease and the risk of too much exercise

Peter Attia MD

A class of diabetic drugs that block sodium-glucose co-transporter in kidneys, leading to glucose excretion. Surprisingly shown to reduce cardiovascular death, heart failure, and renal failure in people with and without diabetes.

171- Longevity science: caloric restriction studies, aging biomarkers & possible longevity molecules

Peter Attia MD

A class of drugs showing remarkable human data on kidney failure, all-cause mortality, and heart failure, with potential benefits in longevity that may not be solely due to caloric reduction.

Dr. Peter Attia — Longevity Drugs, Alzheimer's Disease, and More

Tim Ferriss

A class of drugs including Canagliflozin that block glucose reuptake in the kidneys, causing glucose to be excreted in urine. They are effective for Type 2 diabetes and have shown benefits beyond glucose lowering.

#59–Jason Fung, M.D: Fasting as an antidote to obesity, insulin resistance, T2D, & metabolic illness

Peter Attia MD

A newer class of drugs for diabetic kidney disease that makes patients excrete sugar through urine, showing protective effects against kidney and heart disease, unlike older anti-diabetic drugs.

The Science of Hunger & Medications to Combat Obesity | Dr. Zachary Knight

Andrew Huberman

A class of drugs used for diabetes that block a protein in the kidney, causing glucose to be peed out and leading to weight loss without the individual realizing the energy deficit.

Pros and cons of GLP-1 weight loss drugs and metformin as a geroprotective agent [AMA 45 sneak peek]

Peter Attia MD

A class of drugs that act in the kidneys to reduce glucose reabsorption, mentioned for their potential longevity benefits.

357 ‒ A new era of longevity science: models of aging, rapamycin trials, biological clocks, & more

Peter Attia MD

A class of drugs considered interesting for geroprotection, potentially comparable to rapamycin and GLP-1 agonists. The speaker notes their effect in metabolically healthy individuals is less clear.

All Things Ketones, How to Boost Cognition, Sardine Fasting, Diet Rules, & More — Dr. Dom D’Agostino

Tim Ferriss

230 ‒ Cardiovascular disease in women: prevention, risk factors, lipids, and more

Peter Attia MD

A class of drugs mentioned in passing, with Peter Attia asking about their mechanism of cardiac event reduction beyond weight loss, similar to GLP-1 agonists.